A Phase II, Double-blind, Randomized, Placebo-controlled Study to Investigate Pharmacokinetics (PK), Safety and Efficacy of Intravenous Factor XIII Treatment in Patients With Systemic Sclerosis
Phase of Trial: Phase II
Latest Information Update: 07 Jun 2016
At a glance
- Drugs Factor XIII (Primary)
- Indications Systemic scleroderma
- Focus Therapeutic Use
- Acronyms Sclero XIII
- 11 Feb 2016 Status changed from not yet recruiting to recruiting as reported by United Kingdom Clinical Research Network.
- 23 Oct 2015 As per NCT record planned end date is Sep 2018 and as per UKCRN record it is Jun 2018. Though it is country specific single centre trial, kept it as per NCT as later date.
- 25 Aug 2015 New source identified and integrated (European Clinical Trials Database - EudraCT2014-001101-40).